HCM - Rasio utang marang kapitalisasi buku Hutchison MediPharma

Logo grafis Hutchison MediPharma (HCM)

HUTCHMED (China) Limited (HCM) generates revenue through the development of advanced oncology drugs and the sale of healthcare products in the PRC, with operations that remain entirely independent of economic cycles and seasonal fluctuations. This price chart illustrates the asset's dynamics, where the key indicator is 0.07. Due to its Hong Kong base, the business faces the US-China trade confrontation, which complicates FDA certification.

HUTCHMED (China) Limited - Utang-utang marang kapitalisasi buku HCM (periode 04.07.2022 - 28.10.2026)

Hutchison MediPharma (HCM) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Rega saham HUTCHMED (China) Limited|HCM - Rata-rata rega prakiraan
- data kapitalisasi pasar:
Nilai pasar HUTCHMED Corp|HCM - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Nilai Buku saben Saham HUTCHMED|HCM - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku hutch-med.com|HCM - Aset Agregat Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas HUTCHMED (China) Limited|HCM - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas HUTCHMED Ltd|HCM - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku HUTCHMED Corp|HCM - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan HUTCHMED
Ringkesan analitik perusahaan:HCM - HUTCHMED (China) Limited
Barang utama HUTCHMED Ltd

To assess the long-term sustainability of HUTCHMED (China) Limited (HCM), examine the total liabilities-to-equity ratio, which reflects the proportion of debt financing within the asset structure via the total debt-to-book capitalization coefficient. This trend captures how effectively the company balances its credit load against R&D expenses while scaling oncology drugs in China to accelerate ARR growth.

Pesaing HUTCHMED (China) Limited

INCY: Utang-utang marang kapitalisasi buku|nuvationbio.com - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku Day One Biopharmaceuticals (DAWN)|MNPR - Rasio utang marang aset resik|INBX: Utang-utang marang kapitalisasi buku|IMAB (I-Mab Biopharma) - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Fennec Pharmaceuticals|Rasio utang marang kapitalisasi buku Heron Therapeutics Inc (HRTX)|Nuvectis Pharma (NVCT) - Utang marang nilai buku|Rasio utang marang aset resik CHRS (Coherus Biosciences)|CRBP: Rasio utang marang kapitalisasi buku|Cardiff Oncology Inc. - Utang-utang marang nilai buku|BeyondSpring Inc. (BYSI) - Rasio utang marang kapitalisasi buku|BCAB - Rasio utang marang nilai buku|LIXT (Lixte Biotechnology Holdings, Inc.) - Utang-utang marang kapitalisasi buku|CTXR (Citius Pharmaceuticals, Inc.) - Utang marang nilai buku|Rasio utang marang kapitalisasi buku CLRB (Cellectar)|Utang-utang marang nilai buku BLRX|Rasio utang marang kapitalisasi buku Can-Fite BioPharma (CANF)|Rasio utang marang kapitalisasi buku APRE (aprea.com)|KZIA: Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku Silexion Therapeutics Corp. SLXN|Utang-utang marang kapitalisasi buku NCNA|Chimerix Inc (CMRX) - Utang marang aset resik|Utang marang nilai buku CYCC|Utang-utang marang nilai buku G1 Therapeutics|KRON - Utang marang nilai buku|Rasio utang marang aset resik Kintara Therapeutics Inc (KTRA)|Utang marang nilai buku Oncternal|Utang marang modal buku Portage Biotech Corp (PRTG)